Publications by authors named "Doreen A Ezeife"
Article Synopsis
- New cancer drugs undergo thorough evaluations before being funded in single-payer healthcare systems, focusing on review times and funding outcomes.
- A study analyzing data from the pan-Canadian Oncology Drug Review (pCODR) between 2012 and 2020 found that drugs for gastrointestinal and lung cancers had longer review times compared to others.
- Longer review times correlated with negative funding recommendations, highlighting the need to understand these delays to improve patient access to effective cancer treatments.
Background: Liquid biopsy (LB) can detect actionable genomic alterations in plasma circulating tumor circulating tumor DNA beyond tissue testing (TT) alone in advanced non-small cell lung cancer (NSCLC) patients. We estimated the cost-effectiveness of adding LB to TT in the Canadian healthcare system.
Methods: A cost-effectiveness analysis was conducted using a decision analytic Markov model from the Canadian public payer (Ontario) perspective and a 2-year time horizon in patients with treatment-naïve stage IV non-squamous NSCLC and ⩽10 pack-year smoking history.
Article Synopsis
- Rearrangements in lung adenocarcinoma occur in 1-2% of cases, leading to guideline-recommended reflex testing to improve detection of true positives.
- A decision model was created to evaluate multiple diagnostic strategies, including immunohistochemistry (IHC), fluorescence in-situ hybridization (FISH), and next-generation sequencing (NGS), focusing on optimizing cost and turnaround time (TAT).
- The study found that reflex IHC screening followed by FISH confirmation was the most effective in terms of cost savings and TAT, while clinician-initiated testing was the least expensive but had long delays and missed cases, emphasizing the need for reflex testing.
Unlabelled: INTRODUCTION Advances in novel treatment options may render renal cell cancer (RCC) patients susceptible to the financial toxicity (FT) of cancer treatment, and the factors associated with FT are unknown.
Materials And Methods: Eligible patients were ≥ 18 years old and had a diagnosis of stage IV RCC for at least 3 months. Patients were recruited from Princess Margaret Cancer Centre and Sunnybrook Odette Cancer Centre (Toronto, Canada).
An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access.
Am Soc Clin Oncol Educ Book
March 2021
Increasing cancer drug prices present global challenges to treatment access and cancer outcomes. Substantial variability exists in drug pricing across countries. In countries without universal health care, patients are responsible for treatment costs.
View Article and Find Full Text PDFBackground: Globally, the rising cost of anticancer therapy has motivated efforts to quantify the overall value of new cancer treatments. Multicriteria decision analysis offers a novel approach to incorporate multiple criteria and perspectives into value assessment.
Methods: The authors recruited a diverse, multistakeholder group who identified and weighted key criteria to establish the drug assessment framework (DAF).
Objectives: The authors sought to quantify the treatment patterns and outcomes for limited-stage (LS) and extensive-stage (ES) small cell lung cancer (SCLC) in a real-world setting.
Methods: A review was conducted using the Glans-Look Research Database of patients with SCLC managed at a tertiary cancer center in Canada from 2010 to 2016. Adherence was defined as the commencement of planned SCLC treatment.
Background: Clinical benefit scores (CBS) are key elements of the ASCO Value Framework (ASCO-VF) and are weighted based on a hierarchy of efficacy endpoints: hazard ratio for death (HR OS), median overall survival (mOS), HR for disease progression (HR PFS), median progression-free survival (mPFS), and response rate (RR). When HR OS is unavailable, the other endpoints serve as "surrogates" to calculate CBS. CBS are computed from PFS or RR in 39.
View Article and Find Full Text PDFIntroduction: Financial distress has been established as a clinically relevant patient-reported outcome associated with worse mortality and quality of life. Our goal was to define factors associated with financial burden (FB) in a public health care system.
Materials And Methods: Patients with advanced lung cancer were recruited from outpatient clinics at the Princess Margaret Cancer Centre (Toronto, Canada).
Introduction: Osimertinib improves progression-free survival in previously untreated EGFR-positive advanced non-small cell lung cancer (NSCLC) patients, with marked intracranial response rates. However, its cost-effectiveness in a publically funded health care system has not been established. We assessed the cost-effectiveness of first-line osimertinib from the public payer perspective in the Canadian health care system.
View Article and Find Full Text PDFPhase III trials in metastatic colorectal cancer (mCRC) have collectively led to progressive advancements in patient outcomes over the past decades. This study characterizes the evolution of mCRC phase III trials through assessing the value of cancer therapy, as measured by the ASCO Value Framework. Phase III trial results of systemic therapy for mCRC published between 1980 and 2015 were identified, and their outcome, statistical significance, journal impact factor, and citation by the 2016 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CRC were recorded.
View Article and Find Full Text PDFBackground: The drug approval timeline is a lengthy process that often varies between countries. The objective of this study was to delineate the Canadian drug approval timeline for oncology drugs and to compare the time to drug approval between Health Canada (HC) and the US Food and Drug Administration (FDA).
Methods: In total, 54 antineoplastic drugs that were approved by the FDA between 1989 and 2012 were reviewed.